• Roche and Regeneron are teaming up to develop antibody drugs for COVID-19 treatment.
• Pfizer and BioNTech released early results from its vaccine study showing initial positive responses to one of its two vaccines in development.
• The Food and Drug Administration found positive results in antiviral drug, remdesivir, which assists with recovery in hospitalized COVID-19 patients.

​Recent News:

• Johnson & Johnson to test coronavirus vaccine in 60,000 volunteers
  Reuters- August 20, 2020
  Johnson & Johnson aims to test its experimental coronavirus vaccine in up to 60,000 volunteers in a late-stage trial scheduled to start in September, according to a U.S. government database of clinical trials.
• Pfizer and BioNTech’s favored COVID-19 vaccine has fewer side effects than their first
  STAT – August 20, 2020
  On Thursday, Pfizer and BioNTech posted the results from all 332 people who received either vaccine, referred to as vaccines B1 or B2 — and indeed, B2 recipients experienced markedly fewer adverse events tied to the vaccine.
• What to Know About COVID-19 Tests, from PCR to Antigen to Antibody
  TIME – August 20, 2020 
  The U.S. Food and Drug Administration (FDA) has so far granted emergency-use authorization to more than 200 different tests meant to detect a current or past infection from SARS-CoV-2, the virus that causes COVID-19.
• Roche and Regeneron link up on a COVID-19 antibody drugs
  CNBC – August 19, 2020 
  Regeneron and Roche are teaming up on investigational antibody drugs against COVID-19, with the U.S. company to sell it in the United States and the Swiss drugmaker to sell it elsewhere, should the drug win approval.
• Federal Study of COVID-19 Treatments Enters a New Phase
  New York Times – August 18, 2020
  A large federal study that found an antiviral drug, remdesivir, can hasten the recovery in hospitalized COVID-19 patients, has begun a new phase of investigation.
• Vanda’s experimental COVID-19 drug shows promise in interim trial data
  Reuters – August 18, 2020 
  COVID-19 patients with pneumonia improved faster when treated with Vanda Pharmaceuticals Inc’s experimental therapy than those on placebo, the company said on Tuesday, citing an interim analysis of data from a late-stage study.
• How a biotech CEO figured out COVID-19 surveillance testing for 50 companies with 12-hour turnaround times
  CNBC – August 14, 2020 
  One biotech CEO put together a system for 50 companies that enables researchers to get back to labs safely since clinical research can’t be done from home.
• Inside the multibillion dollar race for a COVID-19 vaccine
  CNN – August 14, 2020 
  Dozens of research teams around the world are working to develop a vaccine COVID-19, using a mix of established techniques and new technologies.